Instructional Leadership, emphasis: K-12 School Leadership (MEd)
Molecular structure and liquids used in research labs
  1. NAU
  2. Research
  3. Innovations
  4. Available technologies
  5. Biomedical innovations
  6. Genotyping of SNP rs13136737 to Stratify Prostate Cancer Risk

Genotyping of SNP rs13136737 to Stratify Prostate Cancer Risk

Description

This technology relates to genotyping one or more single nucleotide polymorphisms (SNPs) to stratify cancer risk and/or prognosis. The single nucleotide polymorphism rs13136737 (G/T) is a poorly-known common genetic variant that is found within the pri-miRNA of the miR-302/367 gene cluster. While expression of the miR302/367 cluster is undetectable in prostate cancer cells, transcription of the cluster is upregulated in tumor-initiating cells. Stem cell transcription factors expressed in the prostate cancer tumor-initiating cells have activated transcription of the miR302-367 cluster. Genotyping results have shown that there is an association correlation between TT-genotype and pathological stage, which indicates the extent of tumor involvement. Thus, men with the TT- genotype in the pluripotency miR302/367 gene cluster have a higher risk of locally invasive prostate cancer.

Additional information

Patent number and inventor

PCT/US2018/044473

Jason Wilder, Kelsey Guest, Ronald Heimark, Virginia Ware, and Christina Laukaitis.

Potential applications

Clinical applications in prostate cancer diagnoses.

Benefits and advantages

This SNP would be important in the decision-making for men with low-grade cancer that are considering “watchful waiting” or prostatectomy, and has a high potential for clinical utility.

Case number and licensing status

2016-035

This invention is available for licensing.